MedImmune, NGM ally to develop drugs for obesity, diabetes

06/18/2013 | PharmaTimes (U.K.)

AstraZeneca's MedImmune unit and NGM Biopharmaceuticals will collaborate in the discovery and development of the latter's enteroendocrine cell program for the treatment of obesity and type 2 diabetes. The firms intend to develop first-in-class peptide and antibody treatments based on the EEC hormones. The deal entitles NGM to upfront payment, research funding, milestone fees and royalties.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA